Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population.

Yasar SattarPradeeksha MukuntharajMohamed ZghouziAbdul-Rahman M SuleimanHassan AttiqueWaqas UllahMuhammad Khawar SanaNathan ZaherMaham MehmoodRajkumar P DoshiAnkur PanchalTanveer MirMuhammad NadeemOmar E AliMohamad MohamedRodrigo BagurIslam Y ElgendyMamas A MamasMohamed Chadi Alraies

Published in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2021)

COVID-19 is not a contraindication to hold or discontinue RAASi as they are not associated with higher mortality or worsening symptoms. Continuation of RAASi might be associated with favorable outcomes in COVID-19, including seropositivity/viral clearance.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
angiotensin ii
angiotensin converting enzyme
risk factors
type diabetes
metabolic syndrome
depressive symptoms
physical activity
insulin resistance
sleep quality
weight loss